• 1.

    Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:14361446. doi: 10.1056/NEJMoa2024816

  • 2.

    U.S. Food and Drug Administration. FDA removes boxed warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Aug. 26, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin

    • Search Google Scholar
    • Export Citation
  • 3.

    Perkovic V, et al. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306. doi: 10.1056/NEJMoa1811744

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Packer M, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:14131424. doi: 10.1056/NEJMoa2022190

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Zannad F, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Reduced Trial. Circulation [published online ahead of print Oct. 23, 2020]. doi: 10.1161/CIRCULATIONAHA.120.051685

    • Search Google Scholar
    • Export Citation
  • 6.

    Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med [published online ahead of print Oct. 23, 2020]. doi: 10.1056/NEJMoa2025845; https://www.nejm.org/doi/full/10.1056/NEJMoa2025845

    • Search Google Scholar
    • Export Citation
  • 7.

    Agarwal R, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019; 394:15401550. doi: 10.1016/S0140-6736(19)32135-X

    • Crossref
    • Search Google Scholar
    • Export Citation

SGLT2 Inhibitors Continue to Show Kidney, Heart Benefits

Restricted access

Results from two major trials of sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of drugs initially developed as a treatment for type 2 diabetes mellitus, add to evidence that the drugs may offer kidney-protecting benefits. The results were presented during the High Impact Clinical Trials session at Kidney Week 2020 Reimagined.

The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) Trial found that the SGLT2 inhibitor dapagliflozin provided heart and kidney benefits regardless of the cause of underlying kidney disease. Results from the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction (EMPEROR-Reduced) of

Save